A citation-based method for searching scientific literature

Donald A Berry, Edwin S Iversen, Daniel F Gudbjartsson, Elaine H Hiller, Judy E Garber, Beth N Peshkin, Caryn Lerman, Patrice Watson, Henry T Lynch, Susan G Hilsenbeck, Wendy S Rubinstein, Kevin S Hughes, Giovanni Parmigiani. J Clin Oncol 2002
Times Cited: 323







List of co-cited articles
777 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
36

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
640
33

The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
A C Antoniou, P P D Pharoah, P Smith, D F Easton. Br J Cancer 2004
278
24

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
Debbie Saslow, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener,[...]. CA Cancer J Clin 2007
24

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
22



Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
811
18

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
623
16

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
16

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
A C Antoniou, A P Cunningham, J Peto, D G Evans, F Lalloo, S A Narod, H A Risch, J E Eyfjord, J L Hopper, M C Southey,[...]. Br J Cancer 2008
295
14

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
12

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
690
12


A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, F Lalloo. J Med Genet 2004
178
11

Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.
Jeffrey A Tice, Steven R Cummings, Rebecca Smith-Bindman, Laura Ichikawa, William E Barlow, Karla Kerlikowske. Ann Intern Med 2008
328
11

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
385
11

Assessing women at high risk of breast cancer: a review of risk assessment models.
Eitan Amir, Orit C Freedman, Bostjan Seruga, D Gareth Evans. J Natl Cancer Inst 2010
251
10

Which risk model to use? Clinical implications of the ACS MRI screening guidelines.
Elissa M Ozanne, Brian Drohan, Phil Bosinoff, Alan Semine, Michael Jellinek, Claire Cronin, Frederick Millham, Dana Dowd, Taryn Rourke, Caroline Block,[...]. Cancer Epidemiol Biomarkers Prev 2013
37
27

Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
484
10

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
538
10

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
10

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
D A Berry, G Parmigiani, J Sanchez, J Schildkraut, E Winer. J Natl Cancer Inst 1997
252
9

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
F J Couch, M L DeShano, M A Blackwood, K Calzone, J Stopfer, L Campeau, A Ganguly, T Rebbeck, B L Weber. N Engl J Med 1997
520
9


Impact of Event Scale: a measure of subjective stress.
M Horowitz, N Wilner, W Alvarez. Psychosom Med 1979
9

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
Marc D Schwartz, Caryn Lerman, Barbara Brogan, Beth N Peshkin, Chanita Hughes Halbert, Tiffani DeMarco, William Lawrence, David Main, Clinton Finch, Colette Magnant,[...]. J Clin Oncol 2004
189
9

Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
Marc D Schwartz, Heiddis B Valdimarsdottir, Beth N Peshkin, Jeanne Mandelblatt, Rachel Nusbaum, An-Tsun Huang, Yaojen Chang, Kristi Graves, Claudine Isaacs, Marie Wood,[...]. J Clin Oncol 2014
143
9

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
David M Euhus, Kristin C Smith, Linda Robinson, Amy Stucky, Olufunmilayo I Olopade, Shelly Cummings, Judy E Garber, Anu Chittenden, Gordon B Mills, Paula Rieger,[...]. J Natl Cancer Inst 2002
115
9

Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
472
9

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
462
9

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
A C Antoniou, R Hardy, L Walker, D G Evans, A Shenton, R Eeles, S Shanley, G Pichert, L Izatt, S Rose,[...]. J Med Genet 2008
121
8

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
B B Roa, A A Boyd, K Volcik, C S Richards. Nat Genet 1996
539
8

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
327
8

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
193
8


Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E Garber, Christina Herold, Leif Ellisen,[...]. Cancer 2015
246
8

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, Eitan Friedman, Shlomo Segev, Paul Renbaum, Rachel Beeri, Moran Gal, Julia Grinshpun-Cohen, Karen Djemal,[...]. Proc Natl Acad Sci U S A 2014
185
8

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
A J Lee, A P Cunningham, K B Kuchenbaecker, N Mavaddat, D F Easton, A C Antoniou. Br J Cancer 2014
128
8

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
8

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
725
8

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
7

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
302
7

Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
L C Hartmann, D J Schaid, J E Woods, T P Crotty, J L Myers, P G Arnold, P M Petty, T A Sellers, J L Johnson, S K McDonnell,[...]. N Engl J Med 1999
911
7

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
7


Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial.
Beth N Peshkin, Tiffani A Demarco, Kristi D Graves, Karen Brown, Rachel H Nusbaum, Diana Moglia, Andrea Forman, Heiddis Valdimarsdottir, Marc D Schwartz. Genet Test 2008
42
16

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
Mark E Robson, Courtney D Storm, Jeffrey Weitzel, Dana S Wollins, Kenneth Offit. J Clin Oncol 2010
293
7

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Tuya Pal, Jenny Permuth-Wey, Judith A Betts, Jeffrey P Krischer, James Fiorica, Hector Arango, James LaPolla, Mitchell Hoffman, Martin A Martino, Katie Wakeley,[...]. Cancer 2005
487
7

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.